Zydus Cadila received emergency use approval from the Drugs Controller DGCI on Friday for the use of "Virafin", Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
A single-dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said
stated that 91.15 per cent of patients who were treated with the antiviral were RT-PCR negative by Day 7. The treatment also reduces hours of supplemental oxygen in patients.
Zydus Cadila’s Pegylated Interferon alpha-2b, was originally approved for Hepatitis C and was launched in the Indian market in 2011.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
